Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Casar said the U.S. government can't sit by idly and do nothing. It needs to do something to address the enormous impact of ...
For high school students interested in science, engineering or research, national competitions can be excellent opportunities ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals reported Q1 2026 progress on its AI-driven drug discovery programs, highlighting its first clinical proof of concept and multiple upcoming trial readouts. The company has ...
Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...
Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised more than $205 million in ...
The real question is not what the technology can do but what it ought to do. People everywhere have woken up and are fighting ...
A Generalized Recursive Regular Expression Synthesis Framework" by Professor Sangki Ko's research team from the Depa ...
In this episode of our local program Making Democracy Work, host Lynn Schirk speaks with Dr. Kevin Evans, professor of ...
Cognition makes Devin, the first and arguably most successful AI coding agent. But famed coder Wu says it isn't designed to supplant human programmers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results